Janssen Prods Company Profile
✉ Email this page to a colleague
What is the competitive landscape for JANSSEN PRODS
JANSSEN PRODS has nine approved drugs.
There are seventeen US patents protecting JANSSEN PRODS drugs.
Summary for Janssen Prods
| US Patents: | 17 |
| Tradenames: | 8 |
| Ingredients: | 6 |
| NDAs: | 9 |
Drugs and US Patents for Janssen Prods
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Janssen Prods | PREZISTA | darunavir | TABLET;ORAL | 021976-003 | Oct 21, 2008 | DISCN | Yes | No | 7,700,645*PED | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Janssen Prods | SYMTUZA | cobicistat; darunavir; emtricitabine; tenofovir alafenamide fumarate | TABLET;ORAL | 210455-001 | Jul 17, 2018 | RX | Yes | Yes | 8,148,374 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Janssen Prods | EDURANT PED | rilpivirine hydrochloride | TABLET, FOR SUSPENSION;ORAL | 219016-001 | Mar 15, 2024 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| Janssen Prods | PREZCOBIX | cobicistat; darunavir ethanolate | TABLET;ORAL | 205395-002 | Mar 21, 2025 | RX | Yes | Yes | 10,039,718 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Janssen Prods | OLYSIO | simeprevir sodium | CAPSULE;ORAL | 205123-001 | Nov 22, 2013 | DISCN | Yes | No | 9,353,103 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Janssen Prods | PREZISTA | darunavir | SUSPENSION;ORAL | 202895-001 | Dec 16, 2011 | RX | Yes | Yes | 7,700,645*PED | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Janssen Prods
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Janssen Prods | EDURANT | rilpivirine hydrochloride | TABLET;ORAL | 202022-001 | May 20, 2011 | 6,838,464 | ⤷ Start Trial |
| Janssen Prods | EDURANT | rilpivirine hydrochloride | TABLET;ORAL | 202022-001 | May 20, 2011 | 8,080,551 | ⤷ Start Trial |
| Janssen Prods | EDURANT | rilpivirine hydrochloride | TABLET;ORAL | 202022-001 | May 20, 2011 | 7,638,522 | ⤷ Start Trial |
| Janssen Prods | SYMTUZA | cobicistat; darunavir; emtricitabine; tenofovir alafenamide fumarate | TABLET;ORAL | 210455-001 | Jul 17, 2018 | 7,390,791 | ⤷ Start Trial |
| Janssen Prods | OLYSIO | simeprevir sodium | CAPSULE;ORAL | 205123-001 | Nov 22, 2013 | 9,040,562 | ⤷ Start Trial |
| Janssen Prods | PREZCOBIX | cobicistat; darunavir ethanolate | TABLET;ORAL | 205395-001 | Jan 29, 2015 | 9,889,115 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for JANSSEN PRODS drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 800 mg | ➤ Subscribe | 2013-05-14 |
International Patents for Janssen Prods Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Denmark | 1567529 | ⤷ Start Trial |
| Japan | 2006124393 | ⤷ Start Trial |
| Montenegro | 02582 | ⤷ Start Trial |
| Portugal | 2487162 | ⤷ Start Trial |
| Slovenia | 2393485 | ⤷ Start Trial |
| Eurasian Patent Organization | 200800476 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Janssen Prods Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2487166 | 201640056 | Slovenia | ⤷ Start Trial | PRODUCT NAME: COBICISTAT OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND TENOFOVIR ALAFENAMIDE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, ESPECIALLY TENOFOVIR ALAFENAMIDE FUMARATE; NATIONAL AUTHORISATION NUMBER: EU/1/15/1061/001-002; DATE OF NATIONAL AUTHORISATION: 20151119; AUTHORITY FOR NATIONAL AUTHORISATION: EU |
| 2049506 | C201530064 | Spain | ⤷ Start Trial | PRODUCT NAME: COBICISTAT O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO; NATIONAL AUTHORISATION NUMBER: EU/1/13/830; DATE OF AUTHORISATION: 20130524; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/13/830; DATE OF FIRST AUTHORISATION IN EEA: 20130524 |
| 2487162 | SPC/GB17/009 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: COBICISTAT OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF AND DARUNAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF; REGISTERED: UK EU/1/14/967 20141121 |
| 2049506 | 92864 | Luxembourg | ⤷ Start Trial | PRODUCT NAME: COBICISTAT OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; AUTHORISATION NUMBER AND DATE: EU/1/13/830/001-002 20130527 |
| 3150586 | 301045 | Netherlands | ⤷ Start Trial | PRODUCT NAME: COBICISTAT OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF SOLVAAT DAARVAN, DARUNAVIR OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF SOLVAAT DAARVAN, IN HET BIJZONDER DARUNAVIRETHANOLAAT, EN EMTRICITABINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF SOLVAAT DAARVAN; REGISTRATION NO/DATE: EU/1/17/1225 20170925 |
| 1632232 | 300853 | Netherlands | ⤷ Start Trial | PRODUCT NAME: COMBINATIE VAN: - RILPIVIRINEHYDROCHLORIDE OF EEN THERAPEUTISCH EQUIVALENTE VORM DAARVAN ZOALS BESCHERMD DOOR HET BASISOCTROOI; EN - TENOFOVIRALAFENAMIDE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, IN HET BIJZONDER TENOFOVIRALAFENAMIDEFUMARAAT; REGISTRATION NO/DATE: EU/1/16/1112 20160623 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
